Hoffmann-la Roche

This study tests an experimental drug called Afimkibart (RO7790121) in 160 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it improves skin symptoms like redness and itching better than a placebo. Participants receive the drug or placebo for sever…

This study tests whether adding the experimental drug glofitamab to standard chemotherapy (gemcitabine plus oxaliplatin) helps people with relapsed or refractory diffuse large B-cell lymphoma live longer compared to the usual treatment (rituximab plus same chemo). About 270 adult…

This study tests a new medicine, crovalimab, in adults and teenagers with a rare blood disease called atypical hemolytic uremic syndrome (aHUS). The goal is to see if the drug can control the disease by stopping damage to small blood vessels and improving kidney function. Partici…

This study tests whether an eye injection called faricimab, given every 24 weeks, can safely maintain or improve vision in people with wet age-related macular degeneration (nAMD) who have not been treated before. About 274 participants will receive the drug and be followed for 10…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes 557 adults whose cancer worsened after initial treatment with atezolizumab and bevacizumab. …

This study tests whether ocrelizumab (Ocrevus) can slow disability worsening in adults with primary progressive multiple sclerosis (PPMS), including those with more advanced disease. About 1,000 participants receive either the drug or a placebo, and researchers measure changes in…

This study tests whether a new drug called crovalimab works as well as the current standard treatment eculizumab for people with PNH, a rare blood disease that destroys red blood cells. About 210 adults who have not received prior complement inhibitor therapy will be randomly ass…

This study tests a new drug, giredestrant, combined with palbociclib against the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive either the new combo or the standard one.…

This early-phase study tests a drug called inavolisib, alone or with immunotherapy (atezolizumab or pembrolizumab), in 30 adults with cancers that have a specific genetic change (PIK3CA mutation), including advanced head and neck cancer. The main goals are to check safety and see…

This study tests whether adding obinutuzumab to standard treatment helps people with lupus-related kidney disease (lupus nephritis). The trial includes 271 adults with active kidney inflammation. Researchers measure if the drug improves kidney function and reduces protein in urin…

This study tests whether ocrelizumab works better than fingolimod at preventing relapses in children and teens (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug for at least 24 weeks, and researchers track relapse rates and brain …

This study tests whether adding tiragolumab to standard atezolizumab and chemotherapy helps people with untreated extensive-stage small cell lung cancer live longer without their cancer growing. About 123 participants in China will receive either the triple combination or a place…

This study tests whether adding a new drug called inavolisib to two standard treatments (palbociclib and fulvestrant) can help people with a certain type of advanced breast cancer live longer without their disease getting worse. The cancer must have a specific gene mutation (PIK3…

This study tests a combination of two drugs, mosunetuzumab and lenalidomide, in people with follicular lymphoma, a type of blood cancer. The goal is to see if the combo is safe and works better than standard treatments. About 237 adults whose cancer has returned or needs treatmen…

This study follows about 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will track vision changes, eye thickness, and treatment patterns over one year to see how …

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in people with relapsing multiple sclerosis (MS) compared to the standard dose. About 864 adults with MS will receive either the higher or standard dose every 24 weeks. The main …

This study compares a new drug, obinutuzumab, to a standard treatment (MMF) in children and young adults with a kidney condition called nephrotic syndrome, which causes swelling and protein in urine. The goal is to see if obinutuzumab can keep the disease in remission longer and …

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in adults with primary progressive multiple sclerosis (PPMS). About 769 participants receive either the approved dose or a higher dose every 24 weeks. The main goal is to see if …

This study offers ongoing treatment with alectinib or crizotinib to people with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche study. About 200 participants will continue their medication while doctors monitor for side effects and saf…

This study looks at the long-term safety and effectiveness of the drug ocrelizumab in people with multiple sclerosis (MS). About 1,300 participants who were already taking ocrelizumab in earlier studies will continue treatment and be monitored for side effects and disease progres…

This study tests whether adding the drug giredestrant to the standard treatment Phesgo can help people with a certain type of advanced breast cancer (HER2-positive and estrogen receptor-positive) live longer without their cancer getting worse. About 922 participants who have not …

This study tests an experimental pill (RO7269162) in 256 adults who are at risk for or in early stages of Alzheimer's disease. Participants take the pill or a placebo daily for about 1.5 years. Researchers check for side effects and measure changes in brain plaques and other mark…

This study offers continued access to the cancer drug atezolizumab for people who were already in a Roche-sponsored trial and still need treatment. About 49 participants will keep receiving their therapy while doctors monitor for serious side effects. The goal is to provide unint…

This study tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without their cancer growing. Participants must have stable disease or better after initial chemotherapy. The trial compares t…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and trastuzumab can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants will receive treatment…

This study tests whether giving cancer drugs based on the unique genetic changes in a person's tumor can shrink or control advanced solid cancers. About 920 adults and children with tumors that have spread or cannot be removed will receive a treatment chosen specifically for thei…

This study tests a drug called entrectinib in children and teens whose solid tumors or brain tumors have returned or haven't responded to other treatments. The drug targets specific gene changes (NTRK or ROS1 fusions) that help the cancer grow. The goal is to find the best dose a…

This study looks at how a medicine called emicizumab affects the joints, physical activity, and overall health of people aged 13 to 69 with moderate or severe hemophilia A. Participants receive emicizumab as a shot to prevent bleeding episodes. The goal is to see if it improves j…

This study tests whether adding tiragolumab to atezolizumab can help prevent esophageal cancer from growing back after initial chemoradiotherapy. About 760 adults with advanced esophageal cancer that cannot be surgically removed will receive either the drug combination, atezolizu…

This study tests an experimental drug called RO7126209 in people with early to moderate Alzheimer's disease. The main goal is to see if the drug is safe and how it affects amyloid plaques in the brain. About 241 participants will receive multiple doses of the drug or a placebo th…

This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate tumors in people with locally advanced rectal cancer. About 58 participants will receive either the drug combination or atezolizumab alone befor…

This study tests a new medicine called faricimab for people with vision loss caused by severe nearsightedness. About 280 participants will receive either faricimab or an existing treatment (ranibizumab) as eye injections as needed. The goal is to see if faricimab can improve or m…

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps people with obesity or overweight lose more weight over 48 weeks. About 285 adults who have at least one weight-related health issue (like high blood pressur…

This study tests whether adding an experimental drug (RO7204239) that helps muscles grow to an approved SMA treatment (risdiplam) can improve motor function more than risdiplam alone. About 259 people with SMA, aged 2 to 25 years, will take part. The trial first finds the best do…

This study gives patients with solid tumors continued access to the cancer drug pertuzumab if they were already taking it in a previous Roche-sponsored study and their doctor believes they are still benefiting. The goal is to monitor long-term safety and how well the drug control…

This study tests a medicine called emicizumab in babies from birth to 12 months old who have severe hemophilia A. The goal is to see if the medicine can prevent bleeding episodes. Babies receive a shot every 2 weeks for a year, then continue treatment for up to 7 more years. This…

This study tests an antibody called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. The drug aims to block a protein that limits muscle growth, potentially preserving or improving muscle volume. Participa…

This study tests a new medicine called crovalimab in about 50 people with a rare blood disease called PNH. The goal is to see if the drug can control the breakdown of red blood cells and reduce the need for blood transfusions. Participants must be at least 12 years old and have n…

This study tests a drug called cevostamab in 90 people whose multiple myeloma has returned or stopped responding to other treatments. The drug is given through a vein and aims to shrink or control the cancer. The study checks how well it works and what side effects occur.

This study tests a new medicine called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 400 adults who haven't responded well to other treatments will receive either the drug or a placebo. The goal…

This study was designed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS), a condition that increases clot risk. It was a Phase 2 trial for adults aged 18-70 with a history of multiple clots…

This study tests whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (T-DM1) can prevent breast cancer from returning in people with HER2-positive breast cancer who still have cancer cells after initial treatment and surgery. About 1,1…

This study tests two new drug combinations (tobemstomig alone or with tiragolumab) against an existing drug (atezolizumab) in 204 people with advanced bladder cancer who cannot receive platinum chemotherapy. The goal is to see if these combinations are safer and more effective. P…

This study tests a new treatment called OpRegen, made from stem cells, for people with advanced dry age-related macular degeneration (geographic atrophy). The cells are placed under the retina to replace damaged support cells. The main goal is to check safety, but researchers als…

This study tests if refilling a tiny eye implant every 36 weeks works as well as refilling it every 24 weeks for people with wet age-related macular degeneration (nAMD). The implant delivers medicine to control the disease and prevent vision loss. About 451 participants who have …

This study tests a new drug, entrectinib, against the current standard drug, crizotinib, in people with a specific type of advanced lung cancer (ROS1-positive). About 220 participants will take one of the two pills daily. The goal is to see which drug works better at stopping the…

This study tested a daily oral medicine called risdiplam in 26 infants who have a genetic diagnosis of spinal muscular atrophy (SMA) but do not yet show symptoms. The goal was to see if starting treatment early helps them reach motor milestones like sitting without support. Resul…

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has not been treated yet. The drug works by helping the immune system fight cancer cells. The main goal is to see how long people live and how long the cancer stays under contro…

This study tests a new drug called zifibancimig for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is given as an eye injection or through a small implant in the eye to deliver medicine continuously. The goal is to see if it is sa…

This study tests a new drug called crovalimab against the current standard treatment eculizumab in about 190 people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants must already be on complement inhibitor therapy. The goal is to see if crovalima…

This early-phase trial is testing an experimental drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (including breast cancer) that have spread or come back after prior treatment. The study includes people with or without brain metastas…

This study offers continued treatment with atezolizumab (alone or with other drugs) to cancer patients who were benefiting from it in a previous Roche-sponsored trial but lack local access. Up to 1,000 participants will receive the therapy and be monitored for serious side effect…

This study is testing a new drug called glofitamab, alone or with another drug (obinutuzumab), in about 940 people whose B-cell non-Hodgkin's lymphoma has come back or stopped responding to standard treatments. The goal is to find the safest and most effective dose and see how we…

This study tests two new drug combinations for people with advanced kidney cancer that has not been treated before. About 199 participants will receive either a standard treatment or one of two experimental combos that pair immunotherapy with a targeted therapy. The goal is to se…

This study follows over 2,700 patients with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled trial setting. The …

This study is gathering long-term information from about 6,000 people receiving Roche eye medications for conditions like age-related macular degeneration and diabetic eye disease. The goal is to see how well these treatments work in everyday medical practice, not in a controlled…

This study is observing nearly 3,000 people newly diagnosed with breast cancer in Latin America. Researchers are collecting information on how the cancer is diagnosed, what treatments are used, and how patients respond over time. The goal is to better understand real-world care p…